Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2025)

Spero Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $0.56 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 247.37% year-over-year to $0.56; the TTM value through Dec 2025 reached $0.15, up 111.81%, while the annual FY2025 figure was $0.15, 111.81% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.56 in Q4 2025 per SPRO's latest filing, up from -$0.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.97 in Q4 2023 to a low of -$1.01 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.22, with a median of -$0.25 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 433.33% in 2024, then surged 247.37% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.92 in 2021, then soared by 201.09% to $0.93 in 2022, then rose by 4.3% to $0.97 in 2023, then plummeted by 139.18% to -$0.38 in 2024, then soared by 247.37% to $0.56 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EPS (Weighted Average and Diluted) are $0.56 (Q4 2025), -$0.13 (Q3 2025), and -$0.03 (Q2 2025).